Drug Database
FR

Fraction F (Fraction F / Ateroid / Ateroid 200)

✓ Approved

Gentium · 治疗药物

什么是 Fraction F?

Fraction F 是一种治疗药物,由Gentium研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Oral (PO)。

药物档案

商品名Fraction F, Ateroid, Ateroid 200
公司Gentium
给药途径Injectable (Others), Intravenous (IV), Oral (PO)
状态Approved

治疗适应症

Fraction F 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersDementia Alzheimer's type✓ Approved

相关研究文献

PubMedFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026-11-19

Sleep-Deprivation Serum Induces Mitochondrial Stress in BV2 Cells: Responses to P2Y12-Targeted Pharmacological Modulation.

Hao Ya Y, Su Lihan L, Liu Xinghua X, Yao Di D et al.

Sleep deprivation (SD) disrupts neuroimmune and metabolic homeostasis, but whether circulating factors generated after sleep loss alter microglial responses to purinergic pharmacological modulation remains unclear. P2Y12 is a microglia-enriched purinergic receptor that regulates process dynamics, calcium signaling, and microglial interactions with neurons and vascular-glial interfaces. Here, we established an in vitro serum-transfer model to test whether serum from sleep-deprived mice alters mitochondrial and Rhod-2 fluorescence responses to P2Y12-targeted compounds in BV2 cells. Mice were subjected to forced-wheel SD consisting of one wheel revolution every 2 s for 4 h per day over 4 consecutive days, and serum was obtained by cardiac blood collection followed by centrifugation. BV2 cells were treated with control or SD serum in the absence or presence of the P2Y12 antagonist MRS2395 or the P2Y12 agonist 2-MeSADP. Mitochondrial membrane potential was assessed by JC-1 red/green ratio imaging, mitochondrial network integrity by MitoTracker-based segmentation and skeletonization, and Rhod-2 fluorescence responses by single-cell F/F0 imaging. SD serum decreased the JC-1 ratio, increased maximal depolarization, reduced mitochondrial skeleton length and mitochondrial area fraction, and suppressed Rhod-2 responses. Under control-serum conditions, MRS2395 markedly enhanced Rhod-2 responses, whereas the increase in the area under the Rhod-2 response curve with 2-MeSADP was not significant after Holm correction. Under SD-serum conditions, however, neither compound consistently restored the mitochondrial or Rhod-2 response profile. Together, these findings link SD-serum exposure to mitochondrial impairment and attenuated Rhod-2 fluorescence responses in BV2 cells, and suggest that serum context may influence cellular responses to P2Y12-targeted compounds.

PMID 43053568
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Harnessing Asymmetric Electrode Dissolution for Highly Reversible Fluorination of Trivalent Metals to Enable Long-Life F-Ion Batteries.

Li Guyue G, Chen Keyi K, Cao Runyuan R, Meng Yuan Y et al.

Fluoride-ion batteries (FIBs), owing to high theoretical energy density, are regarded as a key developmental direction for next-generation energy storage systems. However, during cycling, FIBs suffer from the dissolution loss of active materials and the formation of electron-ion insulated fluorination products, which severely hinders interfacial reaction kinetics and cycle stability. To address these challenges, we propose a synergistic strategy that integrates multiscale solvent screening with the regulation of asymmetric electrode dissolution mechanism, enabling highly reversible and low-polarization fluorination-defluorination in trivalent metal electrodes. We identify an ideal weakly coordinating solvent that ensure sufficient dissociation of fluoride salt while optimizing the chemical environment at electrolyte-electrode interface. On the cathode side, a solid-state migration-fluorination-defluorination mechanism is established to minimize active-material dissolution, thus fundamentally improving the cycling stability. On the anode side, leveraging the high charge density and strong F--coordination affinity of Al3+, we convert the insoluble AlF3 to soluble Al-F complexes and construct a complexation-dissolution-redeposition mechanism. This prevents the fluorinated passivation commonly observed in Zn/Mg anodes and markedly lowers the interfacial electron/ion transport barriers. Benefiting from this approach, the FeF3||Pb full cell retains at least 2000 cycles, and the reversible operation of Al anodes in FIBs is demonstrated for the first time.

PMID 43053381
阅读全文 →
PubMedBMC infectious diseases2026-11-19

Effectiveness of a direct switch to Bictegravir/Emtricitabine/Tenofovir alafenamide in people living with HIV experiencing first-line treatment failure: a real-world study.

Yin Min M, Li Fei F, Zhang Qian Q, Yuan Ziqing Z

In China, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)- or Protease Inhibitor (PI)/boosted regimens with two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are common first-line Antiretroviral Therapy (ART) for People living with HIV (PLWH). Genotypic resistance testing is often unavailable or delayed after treatment failure. The effectiveness of direct switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) following first-line failure in Chinese PLWH is uncertain and requires further investigation. A total of 68 PLWH with plasma HIV RNA > 200 copies/mL while receiving first-line ART were directly switched to B/F/TAF between January 2022 and December 2023. Genotypic resistance testing was performed in individuals with viral load (VL) > 1000 copies/mL. Virologic suppression, CD4 cell recovery, and adverse events were evaluated at week 24 (W24) and 48 (W48). There were 61 (90%) on NNRTI-based regimens and 7 (10%) on PI-based regimens at baseline. Among 49 individuals with VL > 1000 copies/mL, 21(42.9%) had NRTI RAMs, 26(53.0%) had NNRTI RAMs, 3(6.1%) had PI-related mutations. The intention-to-treat (ITT) analysis indicated the virologic suppression rate was 61.7% (42/68) at W24 and 72.1%(49/68) at W48. Meanwhile, the per-protocol (PP) analysis indicated the virologic suppression rate was 93.3%(42/45) at W24 and 100% (49/49) at W48. Notably, the cohort included participants with pre-existing NRTI/NNRTI RAMs. Most mutation carriers achieved virologic suppression after regimen switching.The median CD4 count was increased from 199 [interquartile range(IQR): 85-347] cells/µL at W0 up to 346 (IQR: 178-507) cells/µL at W24 and 410(IQR:200-577) cells/µL at W48 (P = 0.002, P < 0.001, respectively). Our study indicated that direct switch to B/F/TAF after first-line treatment failure achieved 72.1% virological suppression rate in ITT analysis and 100% virologic suppression rate in PP analysis at W48, suggesting that B/F/TAF may serve as an effective salvage therapy for PLWH with pre-existing NRTI RAMs in China in the setting of genotypic resistance testing is unavailable timely.

PMID 43052820
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Tricuspid regurgitation is a barrier to guideline-directed medical therapy implementation in patients with acute decompensated heart failure and reduced ejection fraction.

Brollo Enrico E, Cocianni Daniele D, Barbisan Davide D, Perotto Maria M et al.

Guideline-directed medical therapy (GDMT) reduces mortality in heart failure with reduced ejection fraction (HFrEF), but multiple barriers prevent the correct implementation of recommended treatments. We sought to evaluate the role of tricuspid regurgitation (TR) as an obstacle for GDMT implementation in a cohort of HFrEF patients after an episode of acute decompensated heart failure (ADHF). We enrolled patients hospitalized for ADHF with left ventricular ejection fraction (LVEF) ≤ 40%. TR severity was categorized as moderate-severe or trivial-mild. Optimization of renin-angiotensin system inhibitors/angiotensin receptor-neprilysin inhibitors (RASi/ARNi), beta-blockers and mineralocorticoid receptor antagonists (MRA) therapy was defined when patients were prescribed these drugs at ≥50% of the target dose (TD) at 1-year follow-up. 858 patients were enrolled. At 12 months, patients receiving ≥50% TD of RASi/ARNi, beta-blockers and MRA were 51%, 29%, and 47% respectively. After adjustment for multiple confounders, moderate-severe TR was inversely associated with the likelihood of ≥50% TD up-titration of RASi/ARNi (OR = 0.572, P = .029) and of beta-blockers (OR = 0.526, P = .038), but not of MRA (OR = 0.995, P = .984). RASi/ARNi and beta-blockers optimization was associated with lower 1- and 5-years all-cause mortality risk regardless the severity of TR. The association between RASi/ARNi optimization and 5-years survival was more pronounced in patients with moderate-severe TR vs patients with trivial-mild TR (P for int = .039). The severity of TR in ADHF is a determinant of poor implementation of RASi/ARNi and beta-blockers therapy at 1-year follow-up; however, the lower mortality associated with treatment optimization was not influenced by TR severity.

PMID 43053843
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

TAVR versus surveillance in patients with moderate aortic stenosis and heart failure: a conversion-censored analysis of the TAVR UNLOAD trial.

von Stein Philipp P, Redfors Bjorn B, Snyder Clayton C, Spitzer Ernest E et al.

The neutral TAVR UNLOAD trial randomized patients with heart failure with reduced ejection fraction and moderate aortic stenosis (AS) to transcatheter aortic valve replacement (TAVR) or clinical AS surveillance (CASS). Frequent conversion from CASS to TAVR, primarily due to AS progression, potentially reduced the benefit of TAVR vs CASS. To identify conversion predictors and evaluate outcomes censoring CASS patients at conversion. Patients eligible for balloon-expandable transfemoral TAVR were 1:1 randomized to TAVR or CASS. The hierarchical primary endpoint comprised all-cause death, disabling stroke, heart failure hospitalization/equivalents, and quality of life change. Analyses were performed to longest follow-up, censoring CASS patients at TAVR. Baseline predictors of conversion were identified using cause-specific multivariable Cox regression. Between 2017 and 2022, 178 patients (77 ± 9 years; 21% female; 56% New York Heart Association ≥ III) were randomized (TAVR n ampa#thinsp;89; CASS n ampa#thinsp;89). During a median follow-up of 690 days, 38 CASS patients (43%) underwent TAVR after a median of 366 days. After censoring, the primary endpoint favoured TAVR over CASS [50% vs 30% wins; 20% ties; win ratio: 1.68 (95% CI: 1.16-2.43); P = .006]. Adjusting for age, sex, atrial fibrillation, and left ventricular ejection fraction, the mean aortic valve gradient was the only independent conversion predictor [HR per mmHg: 1.09 (95% CI: 1.02-1.16); P = .015]. In patients with heart failure with reduced ejection fraction and moderate AS, TAVR conferred benefit over CASS when censoring CASS patients at conversion. Although caution is warranted given the observational nature of the comparison, these findings suggest that these patients may derive clinical benefit from TAVR, warranting confirmation in a larger trial.

PMID 43053830
阅读全文 →
PubMedBMC cancer2026-11-19

Anticancer activity of Artemisia biennis L. via induction of apoptosis and regulation of BAX, BCL-2, MMP1, and MMP9 in SW480 colorectal cancer cells.

Farahani Farah F, Khafaji Batoul B, Bidgolian Fatemeh F, Ganji Shahla Mohammad SM

Colorectal cancer is one of the most common malignancies worldwide and, despite recent advances in diagnosis and treatment, it remains associated with high mortality rates. Therefore, there is a growing need for novel therapeutic strategies. Medicinal plants, as natural sources of bioactive compounds, offer promising opportunities for anticancer drug development. The present study aimed to investigate the effects of Artemisia biennis L. on the SW480 colorectal cancer cell line and its impact on the expression of apoptosis-related genes (BAX and BCL-2) and metastasis-related genes (MMP1 and MMP9). Aqueous and butanolic (polar) as well as hexane and ethyl acetate (non-polar) fractions of A. biennis were evaluated at different concentrations and exposure times for their effects on cell growth and viability. The results demonstrated that polar fractions, particularly the aqueous one, significantly reduced SW480 cell viability, with stronger effects observed at longer treatment durations. IC₅₀ values of the polar fractions were lower than those of non-polar fractions. Moreover, BAX gene expression was significantly altered in the hexane fraction, while BCL-2 expression showed notable changes in the aqueous fraction. A decrease in MMP1 and MMP9 expression was also observed in the butanol and ethyl acetate fractions, suggesting reduced migratory potential. In line with these findings, the scratch assay showed that ethyl acetate and butanolic fractions significantly inhibited SW480 cell migration, with the butanolic fraction exerting the strongest anti-migratory effect. Overall, these findings indicate that bioactive compounds from A. biennis can suppress colorectal cancer cell growth through apoptosis induction and consistent with inhibition of migration-related behavior, highlighting their potential for further investigation as anticancer agents.

PMID 43052855
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Fraction F